Citi downgraded Calliditas Therapeutics (CALT) to Neutral from Buy with a $39 price target after Asahi Kasei (AHKSY) announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- CHMP Endorses Calliditas’ Kinpeygo for IgAN
- Calliditas Therapeutics downgraded to Hold from Buy at Jefferies
- Calliditas Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Calliditas Therapeutics downgraded to Hold from Buy at Stifel
- Calliditas Therapeutics presents data at European Renal Association Congress
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue